Clinical trial NCT01163799 - References

Transplant; Failure, Kidney — A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients

Citation(s)

•   Ansari MJ, Sayegh MH
  The arduous road to achieving an immunosuppression-free state in kidney transplant recipients. Nat Clin Pract Nephrol. 2007 Sep;3(9):464-5. Epub 2007 Jul 24. Review.
•   Antonysamy MA, Fanslow WC, Fu F, Li W, Qian S, Troutt AB, Thomson AW
  Evidence for a role of IL-17 in alloimmunity: a novel IL-17 antagonist promotes heart graft survival. Transplant Proc. 1999 Feb-Mar;31(1-2):93.
•   Beninga J, Kropff B, Mach M
  Comparative analysis of fourteen individual human cytomegalovirus proteins for helper T cell response. J Gen Virol. 1995 Jan;76 ( Pt 1):153-60.
•   Besse T, Malaise J, Mourad M, Pirson Y, Hope J, Awwad M, White-Scharf M, Squifflet JP
  Prevention of rejection with BTI-322 after renal transplantation (results at 9 months). Transplant Proc. 1997 Aug;29(5):2425-6.
•   Bishop DK, Chan Wood S, Eichwald EJ, Orosz CG
  Immunobiology of allograft rejection in the absence of IFN-gamma: CD8+ effector cells develop independently of CD4+ cells and CD40-CD40 ligand interactions. J Immunol. 2001 Mar 1;166(5):3248-55.
•   Bobadilla JL, Love RB, Jankowska-Gan E, Xu Q, Haynes LD, Braun RK, Hayney MS, Munoz del Rio A, Meyer K, Greenspan DS, Torrealba J, Heidler KM, Cummings OW, Iwata T, Brand D, Presson R, Burlingham WJ, Wilkes DS
  Th-17, monokines, collagen type V, and primary graft dysfunction in lung transplantation. Am J Respir Crit Care Med. 2008 Mar 15;177(6):660-8. doi: 10.1164/rccm.200612-1901OC. Epub 2008 Jan 3.
•   Burlingham WJ, Love RB, Jankowska-Gan E, Haynes LD, Xu Q, Bobadilla JL, Meyer KC, Hayney MS, Braun RK, Greenspan DS, Gopalakrishnan B, Cai J, Brand DD, Yoshida S, Cummings OW, Wilkes DS
  IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest. 2007 Nov;117(11):3498-506.
•   Chamian F, Lin SL, Lee E, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Cardinale I, Khatcherian A, Novitskaya I, Wittkowski KM, Krueger JG, Lowes MA
  Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis. J Transl Med. 2007 Jun 7;5:27.
•   Chisholm PL, Williams CA, Jones WE, Majeau GR, Oleson FB, Burrus-Fischer B, Meier W, Hochman PS
  The effects of an immunomodulatory LFA3-IgG1 fusion protein on nonhuman primates. Ther Immunol. 1994 Aug;1(4):205-16.
•   Cooper JC, Morgan G, Harding S, Subramanyam M, Majeau GR, Moulder K, Alexander DR
  Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells. Eur J Immunol. 2003 Mar;33(3):666-75.
•   Crawford K, Gabuzda D, Pantazopoulos V, Xu J, Clement C, Reinherz E, Alper CA
  Circulating CD2+ monocytes are dendritic cells. J Immunol. 1999 Dec 1;163(11):5920-8.
•   Crispim JC, Grespan R, Martelli-Palomino G, Rassi DM, Costa RS, Saber LT, Cunha FQ, Donadi EA
  Interleukin-17 and kidney allograft outcome. Transplant Proc. 2009 Jun;41(5):1562-4. doi: 10.1016/j.transproceed.2009.01.092.
•   da Silva AJ, Brickelmaier M, Majeau GR, Li Z, Su L, Hsu YM, Hochman PS
  Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J Immunol. 2002 May 1;168(9):4462-71.
•   Dasgeb B, Holzman G, Phillips TJ
  An extended 16-week course of alefacept in conjunction with reduced T-cell monitoring for the treatment of chronic plaque psoriasis. Poster P2720, American Academy of Dermatology 2005 Annual Meeting, New Orleans, Louisiana, February 2005.
•   Dhanireddy KK, Bruno DA, Zhang X, Leopardi FV, Johnson LB, et al
  Alefacept (LFA-3-Ig), portal venous donor specific transfusion, and sirolimus prolong renal allograft survival in non-human primates. Abstract 1627, American College of Surgeons 2006 Clinical Congress, Poster Session: Primate Models 2006 Jul 24.
•   Di Pucchio T, Lapenta C, Santini SM, Logozzi M, Parlato S, Belardelli F
  CD2+/CD14+ monocytes rapidly differentiate into CD83+ dendritic cells. Eur J Immunol. 2003 Feb;33(2):358-67.
•   Dustin ML, Springer TA
  Role of lymphocyte adhesion receptors in transient interactions and cell locomotion. Annu Rev Immunol. 1991;9:27-66. Review.
•   Ellis CN, Krueger GG; Alefacept Clinical Study Group
  Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 2001 Jul 26;345(4):248-55.
•   Evans HG, Suddason T, Jackson I, Taams LS, Lord GM
  Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytes. Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17034-9. Epub 2007 Oct 17.
•   Eypasch E, Williams JI, Wood-Dauphinee S, Ure BM, Schmülling C, Neugebauer E, Troidl H
  Gastrointestinal Quality of Life Index: development, validation and application of a new instrument. Br J Surg. 1995 Feb;82(2):216-22.
•   Fábrega E, López-Hoyos M, San Segundo D, Casafont F, Pons-Romero F
  Changes in the serum levels of interleukin-17/interleukin-23 during acute rejection in liver transplantation. Liver Transpl. 2009 Jun;15(6):629-33. doi: 10.1002/lt.21724.
•   Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, van Lier RA, Ten Berge IJ
  Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood. 2003 Apr 1;101(7):2686-92. Epub 2002 Oct 31.
•   Gandhi MK, Khanna R
  Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis. 2004 Dec;4(12):725-38. Review.
•   Gold MH, Hamilton TK, Rynearson A, Mathes B
  An open-label community-based study of an extended course of alefacept in the treatment of chronic plaque psoriasis. Poster P2722, American Academy of Dermatology 2005 Annual Meeting, New Orleans, Louisiana, February 2005.
•   Gonwa T, Mendez R, Yang HC, Weinstein S, Jensik S, Steinberg S; Prograf Study Group
  Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation. 2003 Apr 27;75(8):1213-20.
•   Gribetz CH, Blum R, Brady C, Cohen S, Lebwohl M
  An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. J Am Acad Dermatol. 2005 Jul;53(1):73-5.
•   Humar A, Michaels M; AST ID Working Group on Infectious Disease Monitoring
  American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006 Feb;6(2):262-74.
•   Ibrahim S, Dawson DV, Sanfilippo F
  Predominant infiltration of rejecting human renal allografts with T cells expressing CD8 and CD45RO. Transplantation. 1995 Mar 15;59(5):724-8.
•   Jeong H, Kaplan B
  Therapeutic monitoring of mycophenolate mofetil. Clin J Am Soc Nephrol. 2007 Jan;2(1):184-91. Epub 2006 Nov 8. Review.
•   Johnson C, Ahsan N, Gonwa T, Halloran P, Stegall M, Hardy M, Metzger R, Shield C 3rd, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, Danovitch G, Wachs M, van Veldhuisen P, Salm K, Tolzman D, Fitzsimmons WE
  Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation. 2000 Mar 15;69(5):834-41.
•   Jones ND, Van Maurik A, Hara M, Spriewald BM, Witzke O, Morris PJ, Wood KJ
  CD40-CD40 ligand-independent activation of CD8+ T cells can trigger allograft rejection. J Immunol. 2000 Jul 15;165(2):1111-8.
•   Kaplon RJ, Hochman PS, Michler RE, Kwiatkowski PA, Edwards NM, Berger CL, Xu H, Meier W, Wallner BP, Chisholm P, Marboe CC
  Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival. Transplantation. 1996 Feb 15;61(3):356-63.
•   Kondo T, Takata H, Matsuki F, Takiguchi M
  Cutting edge: Phenotypic characterization and differentiation of human CD8+ T cells producing IL-17. J Immunol. 2009 Feb 15;182(4):1794-8. doi: 10.4049/jimmunol.0801347.
•   Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN; Alefacept Clinical Study Group
  A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2002 Dec;47(6):821-33.
•   Lerut J, Van Thuyne V, Mathijs J, Lemaire J, Talpe S, Roggen F, Ciccarelli O, Zuckermann M, Goffette P, Hope J, Gianello P, Bazin H, Cornet A, Rahier J, Latinne D
  Anti-CD2 monoclonal antibody and tacrolimus in adult liver transplantation. Transplantation. 2005 Nov 15;80(9):1186-93.
•   Loong CC, Hsieh HG, Lui WY, Chen A, Lin CY
  Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection. J Pathol. 2002 Jul;197(3):322-32. Retraction in: J Pathol. 2012 Oct;228(2):260.
•   Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS
  Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol. 1994 Mar 15;152(6):2753-67.
•   Mendez R, Gonwa T, Yang HC, Weinstein S, Jensik S, Steinberg S; Prograf Study Group
  A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation. 2005 Aug 15;80(3):303-9.
•   Miller GT, Hochman PS, Meier W, Tizard R, Bixler SA, Rosa MD, Wallner BP
  Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med. 1993 Jul 1;178(1):211-22.
•   Miller J, Mendez R, Pirsch JD, Jensik SC
  Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation. 2000 Mar 15;69(5):875-80.
•   Mourad M, Besse T, Malaise J, Baldi A, Latinne D, Bazin H, Pirson Y, Hope J, Squifflet JP
  BTI-322 for acute rejection after renal transplantation. Transplant Proc. 1997 Aug;29(5):2353.
•   Newell KA, He G, Guo Z, Kim O, Szot GL, Rulifson I, Zhou P, Hart J, Thistlethwaite JR, Bluestone JA
  Cutting edge: blockade of the CD28/B7 costimulatory pathway inhibits intestinal allograft rejection mediated by CD4+ but not CD8+ T cells. J Immunol. 1999 Sep 1;163(5):2358-62.
•   Olson DP, Dombkowski DM, Kelliher AS, Pontillo C, Anderson DC, Preffer FI
  Differential expression of cell surface antigens on subsets of CD4+ and CD8+ T cells. Med Sci Monit. 2004 Sep;10(9):BR339-45. Epub 2004 Aug 20.
•   Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C
  A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005 Nov;6(11):1133-41. Epub 2005 Oct 2.
•   Preston EH, Xu H, Dhanireddy KK, Pearl JP, Leopardi FV, Starost MF, Hale DA, Kirk AD
  IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion facilitate operational tolerance in non-human primates. Am J Transplant. 2005 May;5(5):1032-41.
•   Putnam Associates, from the results of a survey (funded by Astellas Pharma US, Inc
  ) conducted at the 2004 American Transplant Congress July 14, 2004.
•   Sester M, Sester U, Gärtner B, Heine G, Girndt M, Mueller-Lantzsch N, Meyerhans A, Köhler H
  Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation. 2001 May 15;71(9):1287-94.
•   Sester M, Sester U, Gärtner BC, Girndt M, Meyerhans A, Köhler H
  Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection. J Am Soc Nephrol. 2002 Oct;13(10):2577-84.
•   Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, Campbell PM, Cascalho M, Collins AB, Demetris AJ, Drachenberg CB, Gibson IW, Grimm PC, Haas M, Lerut E, Liapis H, Mannon RB, Marcus PB, Mengel M, Mihatsch MJ, Nankivell BJ, Nickeleit V, Papadimitriou JC, Platt JL, Randhawa P, Roberts I, Salinas-Madriga L, Salomon DR, Seron D, Sheaff M, Weening JJ
  Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant. 2007 Mar;7(3):518-26.
•   Squifflet JP, Bäckman L, Claesson K, Dietl KH, Ekberg H, Forsythe JL, Kunzendorf U, Heemann U, Land W, Morales JM, Mühlbacher F, Talbot D, Taube D, Tyden G, van Hooff J, Schleibner S, Vanrenterghem Y; European Tacrolimus-MMF Renal Study Group
  Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation. 2001 Jul 15;72(1):63-9.
•   Squifflet JP, Besse T, Malaise J, Mourad M, Delcorde C, Hope JA, Pirson Y
  BTI-322 for induction therapy after renal transplantation: a randomized study. Transplant Proc. 1997 Feb-Mar;29(1-2):317-9.
•   Sultan P, Schechner JS, McNiff JM, Hochman PS, Hughes CC, Lorber MI, Askenase PW, Pober JS
  Blockade of CD2-LFA-3 interactions protects human skin allografts in immunodeficient mouse/human chimeras. Nat Biotechnol. 1997 Aug;15(8):759-62.
•   Valujskikh A, Pantenburg B, Heeger PS
  Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice. Am J Transplant. 2002 Jul;2(6):501-9.
•   Van Kooten C, Boonstra JG, Paape ME, Fossiez F, Banchereau J, Lebecque S, Bruijn JA, De Fijter JW, Van Es LA, Daha MR
  Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection. J Am Soc Nephrol. 1998 Aug;9(8):1526-34.
•   Vanaudenaerde BM, Dupont LJ, Wuyts WA, Verbeken EK, Meyts I, Bullens DM, Dilissen E, Luyts L, Van Raemdonck DE, Verleden GM
  The role of interleukin-17 during acute rejection after lung transplantation. Eur Respir J. 2006 Apr;27(4):779-87.
•   Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR
  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995 Oct 19;333(16):1038-44.
•   Wu Z, Bensinger SJ, Zhang J, Chen C, Yuan X, Huang X, Markmann JF, Kassaee A, Rosengard BR, Hancock WW, Sayegh MH, Turka LA
  Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med. 2004 Jan;10(1):87-92. Epub 2003 Nov 30.
•   Yuan X, Ansari MJ, D'Addio F, Paez-Cortez J, Schmitt I, Donnarumma M, Boenisch O, Zhao X, Popoola J, Clarkson MR, Yagita H, Akiba H, Freeman GJ, Iacomini J, Turka LA, Glimcher LH, Sayegh MH
  Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cells. Proc Natl Acad Sci U S A. 2009 Jun 30;106(26):10734-9. doi: 10.1073/pnas.0812538106. Epub 2009 Jun 15.
•   Yuan X, Paez-Cortez J, Schmitt-Knosalla I, D'Addio F, Mfarrej B, Donnarumma M, Habicht A, Clarkson MR, Iacomini J, Glimcher LH, Sayegh MH, Ansari MJ
  A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med. 2008 Dec 22;205(13):3133-44. doi: 10.1084/jem.20081937. Epub 2008 Dec 1.
•   Zhai Y, Meng L, Gao F, Busuttil RW, Kupiec-Weglinski JW
  Allograft rejection by primed/memory CD8+ T cells is CD154 blockade resistant: therapeutic implications for sensitized transplant recipients. J Immunol. 2002 Oct 15;169(8):4667-73.

A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients

Details for clinical trial NCT01163799